Last reviewed · How we verify
LPV/r + TDF/FTC or TDF/3TC
This combination antiretroviral regimen suppresses HIV replication by inhibiting viral protease and reverse transcriptase enzymes simultaneously.
This combination antiretroviral regimen suppresses HIV replication by inhibiting viral protease and reverse transcriptase enzymes simultaneously. Used for HIV-1 infection (treatment and prevention).
At a glance
| Generic name | LPV/r + TDF/FTC or TDF/3TC |
|---|---|
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lopinavir/ritonavir (LPV/r) is a protease inhibitor that blocks HIV protease, preventing viral maturation and release of infectious particles. Tenofovir/emtricitabine (TDF/FTC) or tenofovir/lamivudine (TDF/3TC) are nucleoside reverse transcriptase inhibitors that block reverse transcriptase, preventing conversion of viral RNA to DNA. Together, these agents target two critical steps in the HIV replication cycle.
Approved indications
- HIV-1 infection (treatment and prevention)
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
- Renal dysfunction (TDF-related)
- Bone density loss (TDF-related)
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy (PHASE2)
- Study of Options for Second-Line Effective Combination Therapy (SELECT) (PHASE3)
- RESIST-2: 2nd-line ART for HIV-2 Infection (NA)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: